Relyea Zuckerberg Hanson’s Ocular Therapeutix OCUL Stock Holding History

Relyea Zuckerberg Hanson’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$173K	Hold	17,600	–	–	0.01%	299
2026 Q1	$149K	Hold	17,600	–	–	0.02%	272
2025 Q4	$214K	Hold	17,600	–	–	0.02%	252
2025 Q3	$206K	Hold	17,600	–	–	0.02%	262
2025 Q2	$163K	Hold	17,600	–	–	0.02%	255
2025 Q1	$129K	Hold	17,600	–	–	0.02%	247
2024 Q4	$150K	Hold	17,600	–	–	0.02%	249
2024 Q3	$153K	Hold	17,600	–	–	0.02%	240
2024 Q2	$120K	Hold	17,600	–	–	0.02%	231
2024 Q1	$160K	Hold	17,600	–	–	0.03%	224
2023 Q4	$78.5K	Buy	+17,600	New	+$52K	0.02%	228

Other funds holding OCUL

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Relyea Zuckerberg Hanson's OCUL Position: Q2 2026 in Review

Relyea Zuckerberg Hanson held its Ocular Therapeutix (OCUL) position steady in Q2 2026 at 17,600 shares worth $173K. The position accounts for 0.01% of the portfolio, ranked #299.

Relyea Zuckerberg Hanson first reported a position in OCUL in Q4 2023 and has held it in 11 quarters since. The position peaked at $214K in Q4 2025. 261 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Relyea Zuckerberg Hanson held 17,600 shares of Ocular Therapeutix worth $173K as of Q2 2026.
Relyea Zuckerberg Hanson left its Ocular Therapeutix share count unchanged in Q2 2026.
Ocular Therapeutix made up 0.01% of Relyea Zuckerberg Hanson's portfolio in Q2 2026, its #299 holding.
Relyea Zuckerberg Hanson first reported a position in Ocular Therapeutix in Q4 2023 and has held it in 11 quarters since.
Relyea Zuckerberg Hanson's Ocular Therapeutix position peaked at $214K in Q4 2025.
261 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Relyea Zuckerberg Hanson's 13F filing for Q2 2026, filed 16 Jul 2026.